Literature DB >> 26394555

A reduced risk of stroke with lithium exposure in bipolar disorder: a population-based retrospective cohort study.

Chen-Chia Lan1,2, Chia-Chien Liu3,4, Ching-Heng Lin5, Tzuo-Yun Lan6, Melvin G McInnis7, Chin-Hong Chan8, Tsuo-Hung Lan2,5,8,9,10.   

Abstract

OBJECTIVES: The risk of stroke is increased in patients with bipolar disorder. Lithium exhibits neuroprotective effects but the association between lithium use and the risk of stroke is unknown.
METHODS: A population-based retrospective cohort study was conducted by utilizing the National Health Insurance Research Database in Taiwan. Subjects who had first been diagnosed with bipolar disorder between 2001 and 2006 were identified. A propensity score (PS) for receiving lithium was calculated with variables of age, gender, and comorbidities. The patients with bipolar disorder receiving lithium within the period from diagnosis through to December 2011 were designated as the lithium group (n = 635). A 1:2 ratio was used to select PS-matched subjects with bipolar disorder without lithium use (n = 1,250). Multivariate Cox proportional hazards regression models were used to explore the association, rather than causal inference, of lithium exposure and the risk of stroke.
RESULTS: Of the 1,885 subjects, 86 (4.6%) experienced stroke, including 2.8% of the lithium group and 5.4% of the non-lithium group. Lithium use was associated with a significantly reduced risk of stroke [hazard ratio (HR) = 0.39, 95% confidence interval (CI): 0.22-0.68]. Reduced risks of stroke were also associated with the highest cumulative lithium dose [≥720 defined daily dose (DDD), HR = 0.25, 95% CI: 0.10-0.59], the longest cumulative exposure period (≥720 days, HR = 0.20, 95% CI: 0.06-0.64), and the highest exposure rate (≥2 DDD/day, HR = 0.39, 95% CI: 0.21-0.70).
CONCLUSIONS: Lithium use was significantly related to a reduced risk of stroke in patients with bipolar disorder.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bipolar disorder; lithium; neuroprotection; risk; stroke

Mesh:

Substances:

Year:  2015        PMID: 26394555     DOI: 10.1111/bdi.12336

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  10 in total

1.  Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.

Authors:  Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

2.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 3.  Using Lithium in Older Age Bipolar Disorder: Special Considerations.

Authors:  Jocelyn Fotso Soh; Sivan Klil-Drori; Soham Rej
Journal:  Drugs Aging       Date:  2019-02       Impact factor: 3.923

4.  Low-Dose Lithium Stabilizes Human Endothelial Barrier by Decreasing MLC Phosphorylation and Universally Augments Cholinergic Vasorelaxation Capacity in a Direct Manner.

Authors:  Bert Bosche; Marek Molcanyi; Soham Rej; Thorsten R Doeppner; Mark Obermann; Daniel J Müller; Anupam Das; Jürgen Hescheler; R Loch Macdonald; Thomas Noll; Frauke V Härtel
Journal:  Front Physiol       Date:  2016-12-06       Impact factor: 4.566

5.  Conditional deletion of Rcan1 predisposes to hypertension-mediated intramural hematoma and subsequent aneurysm and aortic rupture.

Authors:  Silvia Villahoz; Paula Sofía Yunes-Leites; Nerea Méndez-Barbero; Katia Urso; Elena Bonzon-Kulichenko; Sagrario Ortega; J Francisco Nistal; Jesus Vazquez; Stefan Offermanns; Juan Miguel Redondo; Miguel R Campanero
Journal:  Nat Commun       Date:  2018-11-15       Impact factor: 14.919

6.  Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis.

Authors:  Sanja Zivkovic; Chan Hee Koh; Nandita Kaza; Caroline A Jackson
Journal:  BMC Psychiatry       Date:  2019-06-20       Impact factor: 3.630

7.  Lithium Reduces Migration and Collagen Synthesis Activity in Human Cardiac Fibroblasts by Inhibiting Store-Operated Ca2+ Entry.

Authors:  Pao-Huan Chen; Cheng-Chih Chung; Yuan-Feng Lin; Yu-Hsun Kao; Yi-Jen Chen
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

8.  Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study.

Authors:  Jake Prillo; Jocelyn Fotso Soh; Outi Linnaranta; Soham Rej; Haley Park; Serge Beaulieu
Journal:  BMC Psychiatry       Date:  2021-11-10       Impact factor: 3.630

Review 9.  Innovative approaches to bipolar disorder and its treatment.

Authors:  Paul J Harrison; Andrea Cipriani; Catherine J Harmer; Anna C Nobre; Kate Saunders; Guy M Goodwin; John R Geddes
Journal:  Ann N Y Acad Sci       Date:  2016-02       Impact factor: 5.691

10.  Network-based approach to prediction and population-based validation of in silico drug repurposing.

Authors:  Feixiong Cheng; Rishi J Desai; Diane E Handy; Ruisheng Wang; Sebastian Schneeweiss; Albert-László Barabási; Joseph Loscalzo
Journal:  Nat Commun       Date:  2018-07-12       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.